Notably, in a CRC mouse model it has been reported that addition of anti-angiogenic therapy reduced intrinsic resistance to an anti-PD-1 antibody via normalizing tumor vascularization and reducing hypoxia[168]. The gene discussed is PDCD1; the disease is colorectal carcinoma.